1. Ashaar-Ghadim, E., Pazhouhandeh, M., Ahmadabadi, M. (2022). Potato Genome Editing Using CRISPR Technologies. gebsj , 11 (2) : 11. DOR:20.1001.1.25885073.1401.11.2.13.2.

2. Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., & Horvath, P. (2007). CRISPR provides acquired resistance against viruses in prokaryotes. Science, 315(5819), 1709-1712. doi:10.1126/science.1138140. [DOI:10.1126/science.1138140] [PMID]

3. Chandrasegaran, S., & Carroll, D. (2016). Origins of Programmable Nucleases for Genome Engineering. Journal of Molecular Biology, 428(5 Pt B), 963-989. doi:10.1016/j.jmb.2015.10.014. [DOI:10.1016/j.jmb.2015.10.014] [PMID] [PMCID]

4. Dziva, F., & Stevens, M. P. (2008). Colibacillosis in poultry: unravelling the molecular basis of virulence of avian pathogenic Escherichia coli in their natural hosts. Avian Pathology, 37(4), 355-366. doi: 10.1080/03079450802216652. [DOI:10.1080/03079450802216652] [PMID]

5. Gehring, A. M., Mori, I., & Walsh, C. T. (1998). Reconstitution and characterization of the Escherichia coli enterobactin synthetase from EntB, EntE, and EntF. Biochemistry, 37(8), 2648-2659. doi: 10.1021/bi9726584. [DOI:10.1021/bi9726584] [PMID]

6. Hille, F., Richter, H., Wong, S. P., Bratovič, M., Ressel, S., & Charpentier, E. (2018). The Biology of CRISPR-Cas: Backward and Forward. Cell, 172(6), 1239-1259. doi: 10.1016/j.cell.2017.11.032. [DOI:10.1016/j.cell.2017.11.032] [PMID]

7. Hryhorowicz, M., Lipiński, D., Zeyland, J., & Słomski, R. (2017). CRISPR/Cas9 Immune System as a Tool for Genome Engineering. Archivum Immunologiae et Therapiae Experimentalis, 65(3), 233-240. doi:10.1007/s00005-016-0427-5. [DOI:10.1007/s00005-016-0427-5] [PMID] [PMCID]

8. Kordzadeh-Kermani, Z., Kheirandish, R., Sasan, H. ( 2023). Delivery methods of CRISPR/Cas-mediated genome editing system. Gebsj,12 (1) ,145-156. DOR:20.1001.1.25885073.1402.12.1.8.2

9. Johnson, J. R., & Russo, T. A. (2002). Extraintestinal pathogenic Escherichia coli: "the other bad E coli". Journal of Laboratory and Clinical Medicine, 139(3), 155-162. doi: 10.1067/mlc.2002.121550. [DOI:10.1067/mlc.2002.121550] [PMID]

10. Loureiro, A., & da Silva, G. J. (2019). CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool. Antibiotics, 8(1), 18. doi:10.3390/antibiotics8010018. [DOI:10.3390/antibiotics8010018] [PMID] [PMCID]

11. Mojica, F. J. M., & Montoliu, L. (2016). On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals. Trends in Microbiology, 24(10), 811-820. doi: 10.1016/j.tim.2016.06.005. [DOI:10.1016/j.tim.2016.06.005] [PMID]

12. Mojica, F. J., & Rodriguez-Valera, F. (2016). The discovery of CRISPR in archaea and bacteria. The FEBS Journal, 283(17), 3162-3169. doi:10.1111/febs.13766. [DOI:10.1111/febs.13766] [PMID]

13. Pakarian, P., & Pawelek, P. D. (2016). Intracellular co-localization of the Escherichia coli enterobactin biosynthetic enzymes EntA, EntB, and EntE. Biochemical and Biophysical Research Communications, 478(1), 25-32. doi:1016/j.bbrc.2016.07.105. [DOI:10.1016/j.bbrc.2016.07.105] [PMID]

14. Poole, K., Young, L., & Neshat, S. (1990). Enterobactin-mediated iron transport in Pseudomonas aeruginosa. Journal of Bacteriology, 172(12), 6991-6996. doi:10.1128/jb.172.12.6991-6996.1990. [DOI:10.1128/jb.172.12.6991-6996.1990] [PMID] [PMCID]

15. Samare Gholami, A., Sasan, H. A., Hashemabadi, M., & Ravan, H. (2019). Design and Construction of Recombinant CRISPR Vector Harboring LRRK2 Gene for Parkinson's Disease. Cell and Tissue Journal, 10(4), 214-225. doi :10.52547/JCT.10.4.214

16. Shmakov, S., Smargon, A., Scott, D., Cox, D., Pyzocha, N., Yan, W., Abudayyeh, O. O., Gootenberg, J. S., Makarova, K. S., Wolf, Y. I., Severinov, K., Zhang, F., & Koonin, E. V. (2017). .Diversity and evolution of class 2 CRISPR-Cas systems. Nature Reviews Microbiology, 15(3), 169-182. doi: 10.1038/nrmicro.2016.184. [DOI:10.1038/nrmicro.2016.184] [PMID] [PMCID]

17. Wang, H., Cao, L., Logue, C. M., Barbieri, N. L., Nolan, L. K., & Lin, J. (2023). Evaluation of immunogenicity and efficacy of the enterobactin conjugate vaccine in protecting chickens from colibacillosis. Vaccine, 41(4), 930-937. doi:10.1016/j.vaccine.2022.12.057. [DOI:10.1016/j.vaccine.2022.12.057] [PMID]

18. Yogaratnam, V. (1995). Analysis of the causes of high rates of carcase rejection at a poultry processing plant. The Veterinary Record, 137(9), 215-217. doi:10.1136/vr.137.9.215. [DOI:10.1136/vr.137.9.215] [PMID]